Chemify Secures $43M in Series A Funding to Transform Molecular Design and Manufacturing

Chemify, a Glasgow-based biotech innovator, has raised $43 million in a Series A funding round spearheaded by Triatomic Capital, marking a major milestone in bringing digital chemistry solutions to market. The round features participation from a diverse consortium of investors including Horizon Ventures, Rocketship Ventures, Possible Ventures, Alix Ventures, Scotland-based Eos Capital, and the UK Government Innovation Accelerators program, alongside returning backer BlueYard Capital.

The Vision Behind Chemify’s Technology

At its core, Chemify is reimagining how molecules are designed and created. The company’s proprietary Chemputation technology leverages artificial intelligence and advanced robotics to explore the vast landscape of molecular possibilities—essentially mapping and accessing combinations of natural elements to create new compounds on demand. Founded in 2019 by University of Glasgow chemist Lee Cronin, Chemify emerged from over a decade of groundbreaking research in digital chemistry methodologies.

“Our fundamental goal has been to transform chemistry from an experimental craft into a programmable discipline,” Cronin explained. The technology enables faster, safer, and more cost-effective discovery of complex molecules compared to traditional laboratory approaches, dramatically compressing timelines from months to weeks.

From Academia to Commercial Impact

Chemify spun out from the University of Glasgow in March 2022, building on research conducted at the Mazumdar-Shaw Advanced Research Centre. The foundational science—refined through over $30 million in prior research investment—developed a novel framework for encoding chemistry as digital instructions. This allows pharmaceutical companies, materials scientists, and industrial partners to design and manufacture molecules with unprecedented precision.

By encoding chemistry into digital blueprints, Chemify eliminates redundant experimentation cycles that traditionally consume enormous resources. The technology promises to accelerate innovation across drug discovery, advanced materials engineering, and green energy applications.

Strategic Partnerships and Market Opportunity

Steve Hochberg, partner at lead investor Triatomic Capital, highlighted the company’s potential: “Chemify addresses a critical bottleneck in molecular design and manufacturing for numerous industries. Their digital-chemistry approach offers a transformative pathway for partners seeking faster innovation cycles.”

Chemify’s go-to-market strategy centers on collaborative partnerships with specialized organizations in pharmaceuticals, advanced materials, and industrial chemicals. Rather than competing directly, the company positions itself as an enabling platform—providing molecular design and synthesis capabilities that solve complex, high-impact challenges.

The combination of capital, investor expertise, and the company’s technological foundation positions Chemify to scale operations and expand its application portfolio across life sciences, materials discovery, and manufacturing optimization.